Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins

Clinica Chimica Acta

Volumn 378, Issue 1-2, 2007, Pages 13-23

  Sjöwall, Christopher ^a   Wetterö, Jonas ^a  

^a Department of Molecular and Clinical Medicine ^*  (Sweden)

Author keywords

Autoantibodies; C reactive protein; Immune complex; Mannose binding lectin; Opsonization; Systemic lupus erythematosus

Indexed keywords

ACUTE PHASE PROTEIN; AUTOANTIBODY; C REACTIVE PROTEIN; MANNOSE BINDING LECTIN; PENTAXIN; SERUM AMYLOID A; SERUM AMYLOID P;

APOPTOSIS; CLINICAL PRACTICE; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; WASTE DISPOSAL;

ACUTE-PHASE PROTEINS; APOPTOSIS; AUTOANTIBODIES; C-REACTIVE PROTEIN; COMPLEMENT C1Q; COMPLEMENT SYSTEM PROTEINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MANNOSE-BINDING LECTIN; SERUM AMYLOID P-COMPONENT;

EID: 33846922298     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.12.002     Document Type: Review

References (163)

1. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
2. Morley J.J., and Kushner I. Serum C-reactive protein levels in disease. Ann NY Acad Sci 389 (1982) 406-418
3. Tillett W.S., and Francis Jr. T. Serological reactions in pneumonia with non-protein somatic fraction of pneumococcus. J Exp Med 52 (1930) 561-571
4. Gotschlich E.C. C-reactive protein. A historical overview. Ann NY Acad Sci 557 (1989) 9-18
5. Garlanda C., Bottazzi B., Bastone A., and Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition and female fertility. Annu Rev Immunol 23 (2005) 337-366
6. Du Clos T.W., and Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 30 (2004) 261-277
7. Shrive A.K., Cheetham G.M., Holden D., et al. Three dimensional structure of human C-reactive protein. Nat Struct Biol 3 (1996) 346-354
8. Kishore U., Ghai R., Greenhough T.J., et al. Structural and functional anatomy of the globular domain of complement protein C1q. Immunol Lett 95 (2004) 113-128
9. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 887 (2000) 80-89
10. Kuta A.E., and Baum L.L. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med 164 (1986) 321-326
11. Calabro P., Willerson J.T., and Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
12. Dong Q., and Wright J.R. Expression of C-reactive protein by alveolar macrophages. J Immunol 156 (1996) 4815-4820
13. Jabs W.J., Logering B.A., Gerke P., et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 33 (2003) 152-161
14. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M., and Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation. Blood 101 (2003) 545-551
15. Zhang D., Jiang S.L., Rzewnicki D., Samols D., and Kushner I. The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J 310 (1995) 143-148
16. Taylor A.W., Ku N.O., and Mortensen R.F. Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-β. J Immunol 145 (1990) 2507-2513
17. Szalai A.J., Wu J., Lange E.M., et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 83 (2005) 440-447
18. Kovacs A., Green F., Hansson L.O., et al. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 178 (2005) 193-198
19. Veldhuijzen van Zanten J.J., Ring C., Carroll D., and Kitas G.D. Increased C-reactive protein in response to acute stress in patients with rheumatoid arthritis. Ann Rheum Dis 64 (2005) 1299-1304
20. Kovacs A., Henriksson P., Hamsten A., Wallén H., Björkegren J., and Tornvall P. Hormonal regulation of circulating C-reactive protein in men. Clin Chem 51 (2005) 911-913
21. Potempa L.A., Zeller J.M., Fiedel B.A., Kinoshita C.M., and Gewurz H. Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 12 (1988) 391-405
22. Potempa L.A., Maldonado B.A., Laurent P., Zemel E.S., and Gewurz H. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol 20 (1983) 1165-1175
23. Wang H.W., and Sui S.F. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem Biophys Res Commun 288 (2001) 75-79
24. Rees R.F., Gewurz H., Siegel J.N., Coon J., and Potempa L.A. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. Clin Immunol Immunopathol 48 (1988) 95-107
25. Diehl E.E., Haines III G.K., Radosevich J.A., and Potempa L.A. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 319 (2000) 79-83
26. Schwedler S.B., Guderian F., Dammrich J., Potempa L.A., and Wanner C. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 18 (2003) 2300-2307
27. Schwedler S.B., Filep J.G., Galle J., Wanner C., and Potempa L.A. C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis 47 (2006) 212-222
28. Zhong W., Zen Q., Tebo J., Schlottmann K., Coggeshall M., and Mortensen R.F. Effect of human C-reactive protein on chemokine and chemotactic factor-induced neutrophil chemotaxis and signaling. J Immunol 161 (1998) 2533-2540
29. Dobrinich R., and Spagnuolo P.J. Binding of C-reactive protein to human neutrophils. Inhibition of respiratory burst activity. Arthritis Rheum 34 (1991) 1031-1038
30. Yates-Siilata K.E., Dahms T.E., Webster R.O., and Heuertz R.M. C-reactive protein increases F-actin assembly and cortical distribution with resultant loss of lamellipod formation in human neutrophils. Cell Biol Int 28 (2004) 33-39
31. Zouki C., Haas B., Chan J.S., Potempa L.A., and Filep J.G. Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol 167 (2001) 5355-5361
32. Woollard K.J., Phillips D.C., and Griffiths H.R. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol 130 (2002) 256-262
33. Tilg H., Vannier E., Vachino G., Dinarello C.A., and Mier J.W. Anti-inflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells. J Exp Med 178 (1993) 1629-1636
34. Szalai A.J., Nataf S., Hu X.Z., and Barnum S.R. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 168 (2002) 5792-5797
35. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 (2003) 398-404
36. Venugopal S.K., Devaraj S., and Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 108 (2003) 1676-1678
37. Potempa L.A., Motie M., Wright K.E., et al. Stimulation of megakaryocytopoiesis in mice by human modified C-reactive protein (mCRP). Exp Hematol 24 (1996) 258-264
38. Khreiss T., Jozsef L., Hossain S., Chan J.S., Potempa L.A., and Filep J.G. Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem 277 (2002) 40775-40781
39. Kresl J.J., Potempa L.A., Anderson B., and Radosevich J.A. Inhibition of mouse mammary adenocarcinoma (EMT6) growth and metastases in mice by a modified form of C-reactive protein. Tumor Biol 20 (1999) 72-87
40. Kakuta Y., Aoshiba K., and Nagai A. C-reactive protein products generated by neutrophil elastase promote neutrophil apoptosis. Arch Med Res 37 (2006) 456-460
41. Schwedler S.B., Amann K., Wernicke K., et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 112 (2005) 1016-1023
42. Saeland E., van Royen A., Hendriksen K., et al. Human C-reactive protein does not bind to FcγRIIa on phagocytic cells. J Clin Invest 107 (2001) 641-643
43. Hundt M., Zielinska-Skowronek M., and Schmidt R.E. Lack of specific receptors for C-reactive protein on white blood cells. Eur J Immunol 31 (2001) 3475-3483
44. Marnell L.L., Mold C., Volzer M.A., Burlingame R.W., and Du Clos T.W. C-reactive protein binds to FcγRI in transfected COS cells. J Immunol 155 (1995) 2185-2193
45. Bodman-Smith K.B., Gregory R.E., Harrison P.T., and Raynes J.G. FcγRIIa expression with FcγRI results in C-reactive protein-and IgG-mediated phagocytosis. J Leukoc Biol 75 (2004) 1029-1035
46. Bharadwaj D., Stein M.P., Volzer M., Mold C., and Du Clos T.W. The major receptor for C-reactive protein on leukocytes is FcγReceptorII. J Exp Med 190 (1999) 585-590
47. Heuertz R.M., Schneider G.P., Potempa L.A., and Webster R.O. Native and modified C-reactive protein bind different receptors on human neutrophils. Int J Biochem Cell Biol 37 (2005) 320-335
48. Manolov D.E., Röcker C., Hombach V., Nienhaus U., and Torzewski J. Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcγRIIa. Arterioscler Thromb Vasc Biol 24 (2004) 2372-2377
49. Devaraj S., Du Clos T.W., and Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 25 (2005) 1359-1363
50. Marnell L., Mold C., and Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117 (2005) 104-111
51. Chang M.K., Binder C.J., Torzewski M., and Witztum J.L. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 99 (2002) 13043-13048
52. Salonen E.M., Vartio T., Hedman K., and Vaheri A. Binding of fibronectin by the acute phase reactant C-reactive protein. J Biol Chem 259 (1984) 1496-1501
53. Suresh M.V., Singh S.K., and Agrawal A. Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem 279 (2004) 52552-52557
54. Das T., Mandal C., and Mandal C. Protein A-a new ligand for human C-reactive protein. FEBS Lett 576 (2004) 107-113
55. Du Clos T.W. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep 23 (1996) 253-260
56. Spronk P.E., Limburg P.C., and Kallenberg C.G. Serological markers of disease activity in systemic lupus erythematosus. Lupus 4 (1995) 86-94
57. Cabral A.R., and Alarcón-Segovia D. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 10 (1998) 409-416
58. Cocca B.A., Cline A.M., and Radic M.Z. Blebs and apoptotic bodies are B cell autoantigens. J Immunol 169 (2002) 159-166
59. Burlingame R.W., Volzer M.A., Harris J., and Du Clos T.W. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 156 (1996) 4783-4788
60. Motie M., Brockmeier S., and Potempa L.A. Binding of model soluble immune complexes to modified C-reactive protein. J Immunol 156 (1996) 4435-4441
61. Mold C., Gewurz H., and Du Clos T.W. Regulation of complement activation by C-reactive protein. Immunopharmacology 42 (1999) 23-30
62. Vaith P., Prasauskas V., Potempa L.A., and Peter H.H. Complement activation by C-reactive protein on the HEp-2 cell substrate. Int Arch Allergy Immunol 111 (1996) 107-117
63. Gershov D., Kim S., Brot N., and Elkon K.B. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192 (2000) 1353-1364
64. Ji S.R., Wu Y., Potempa L.A., Liang Y.H., and Zhao J. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 26 (2006) 935-941
65. Sjöwall C., Wetterö J., Bengtsson T., et al. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. Biochem Biophys Res Commun 352 (2007) 251-258
66. Agrawal A. CRP after 2004. Mol Immunol 42 (2005) 927-930
67. Berman S., Gewurz H., and Mold C. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis. J Immunol 136 (1986) 1354-1359
68. Jarva H., Jokiranta T.S., Hellwage J., Zipfel P.F., and Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 163 (1999) 3957-3962
69. Giannakis E., Jokiranta T.S., Male D.A., et al. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol 33 (2003) 962-969
70. Li S.H., Szmitko P.E., Weisel R.D., et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 109 (2004) 833-836
71. Hutchinson W.L., Koenig W., Fröhlich M., Sund M., Lowe G.D., and Pepys M.B. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 46 (2000) 934-938
72. Pietilä K.O., Harmoinen A.P., Jokiniitty J., and Pasternack A.I. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 17 (1996) 1345-1349
73. Lagrand W.K., Visser C.A., Hermens W.T., et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 100 (1999) 96-102
74. Mazer S.P., and Rabbani L.E. Evidence for C-reactive protein's role in vascular disease: atherothrombosis, immuno-regulation and CRP. J Thromb Thrombolysis 17 (2004) 95-105
75. Niculescu F., and Rus H. The role of complement activation in atherosclerosis. Immunol Res 30 (2004) 73-80
76. Suh W., Kim K.L., Choi J.H., et al. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochem Biophys Res Commun 321 (2004) 65-71
77. Honig S., Gorevic P., and Weissman G. C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 20 (1977) 1065-1070
78. Pepys M.B., Lanham J.G., and De Beer F.C. C-reactive protein in SLE. Clin Rheum Dis 8 (1982) 91-103
79. Linares L.F., Gomez-Reino J.J., Carreira P.E., Morillas L., and Ibero I. C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE). Clin Rheumatol 5 (1986) 66-69
80. Swaak A.J., van Rooyen A., and Aarden L.A. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int 8 (1989) 263-268
81. Williams Jr. R.C., Harmon M.E., Burlingame R., and Du Clos T.W. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 32 (2005) 454-461
82. Barnes E.V., Narain S., Naranjo A., et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 14 (2005) 576-582
83. Bickerstaff M.C., Botto M., Hutchinson W.L., et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5 (1999) 694-697
84. 1 mice treated with C-reactive protein. Clin Immunol Immunopathol 70 (1994) 22-27
85. Rodriguez W., Mold C., Kataranovski M., Hutt J., Marnell L.L., and Du Clos T.W. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 52 (2005) 642-650
86. 1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 48 (2003) 1602-1611
87. Russell A.I., Cunninghame Graham D.S., Shepherd C., et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13 (2004) 137-147
88. Becker G.J., Waldburger M., Hughes G.R., and Pepys M.B. Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 39 (1980) 50-52
89. Hind C.R., Ng S.C., Feng P.H., and Pepys M.B. Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus. Ann Rheum Dis 44 (1985) 260-261
90. ter Borg E.J., Horst G., Limburg P.C., van Rijswijk M.H., and Kallenberg C.G. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 17 (1990) 1642-1648
91. Suh C.H., Jeong Y.S., Park H.C., et al. Risk factors for infection and role of C-reactive protein in Korean patients with systemic lupus erythematosus. Clin Exp Rheumatol 19 (2001) 191-194
92. Fagan E.A., Dyck R.F., Maton P.N., et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Investig 12 (1982) 351-359
93. Vigushin D.M., Pepys M.B., and Hawkins P.N. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91 (1993) 1351-1357
94. Sturfelt G., and Sjöholm A.G. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 75 (1984) 75-83
95. Grützmeier S., and von Schenck H. C-reactive protein-immunoglobulin complexes in two patients with macroglobulinemia. Scand J Clin Lab Invest 47 (1987) 819-822
96. Weiner S.M., Prasauskas V., Lebrecht D., Weber S., Peter H.H., and Vaith P. Occurrence of C-reactive protein in cryoglobulins. Clin Exp Immunol 125 (2001) 316-322
97. Ballou S.P., and Macintyre S.S. Absence of a binding reactivity of human C-reactive protein for immunoglobulin or immune complexes. J Lab Clin Med 115 (1990) 332-338
98. Potempa L.A., Motie M., Anderson B., Klein E., and Baurmeister U. Conjugation of a modified form of human C-reactive protein to affinity membranes for extracorporeal adsorption. Clin Mater 11 (1992) 105-117
99. Maire M.A., Barnet M., Carpentier N., Miescher P.A., and Lambert P.H. Identification of components of IC purified from human sera. I. Immune complexes purified from sera of patients with SLE. Clin Exp Immunol 51 (1983) 215-224
100. Park Y.B., Lee S.K., Kim D.S., Lee J., Lee C.H., and Song C.H. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16 (1998) 283-288
101. Slavikova M., Schmeisser H., Kontsekova E., Mateicka F., Borecky L., and Kontsek P. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. J Interferon Cytokine Res 23 (2003) 143-147
102. Takemura H., Suzuki H., Yoshizaki K., et al. Anti-interleukin-6 autoantibodies in rheumatic diseases: increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 35 (1992) 940-943
103. Sjöwall C., Ernerudh J., Bengtsson A.A., Sturfelt G., and Skogh T. Reduced anti-TNFα autoantibody levels coincide with flare in systemic lupus erythematosus. J Autoimmun 22 (2004) 315-323
104. Gabay C., Roux-Lombard P., de Moerloose P., Dayer J.M., Vischer T., and Guerne P.A. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 20 (1993) 815-821
105. Morita C., Horiuchi T., Tsukamoto H., et al. Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 44 (2001) 2819-2827
106. Parks C.G., Cooper G.S., Dooley M.A., et al. Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States. Ann Rheum Dis 63 (2004) 91-94
107. Parks C.G., Pandey J.P., Dooley M.A., et al. Genetic polymorphisms in tumor necrosis factor (TNF)-α and TNF-β in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1α-889 C/T polymorphism. Hum Immunol 65 (2004) 622-631
108. Schotte H., Schluter B., Rust S., Assmann G., Domschke W., and Gaubitz M. Interleukin-6 promoter polymorphism (- 174 G/C) in Caucasian German patients with systemic lupus erythematosus. Rheumatology 40 (2001) 393-400
109. Mahoney J.A., and Rosen A. Apoptosis and autoimmunity. Curr Opin Immunol 17 (2005) 583-588
110. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
111. Chang M.K., Binder C.J., Miller Y.I., et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 200 (2004) 1359-1370
112. Nauta A.J., Daha M.R., van Kooten C., and Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 24 (2003) 148-154
113. Gregory C.D., and Devitt A. The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?. Immunology 113 (2004) 1-14
114. Emlen W., Niebur J., and Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152 (1994) 3685-3692
115. Perniok A., Wedekind F., Herrmann M., Specker C., and Schneider M. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 7 (1998) 113-118
116. Courtney P.A., Crockard A.D., Williamson K., Irvine A.E., Kennedy R.J., and Bell A.L. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. Ann Rheum Dis 58 (1999) 309-314
117. Davies K.A., Peters A.M., Beynon H.L., and Walport M.J. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest 90 (1992) 2075-2083
118. Davies K.A., Robson M.G., Peters A.M., Norsworthy P., Nash J.T., and Walport M.J. Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum 46 (2002) 1028-1038
119. Baumann I., Kolowos W., Voll R.E., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 46 (2002) 191-201
120. Manderson A.P., Botto M., and Walport M.J. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22 (2004) 431-456
121. Sjöholm A.G., Jönsson G., Braconier J.H., Sturfelt G., and Truedsson L. Complement deficiency and disease: an update. Mol Immunol 43 (2006) 78-85
122. Sturfelt G., Bengtsson A., Klint C., Nived O., Sjöholm A., and Truedsson L. Novel roles of complement in systemic lupus erythematosus - hypothesis for a pathogenetic vicious circle. J Rheumatol 27 (2000) 661-663
123. Talal N., Pillarisetty R.J., DeHoratius R.J., and Messner R.P. Immunologic regulation of spontaneous antibodies to DNA and RNA I. Significance of IgM and IgG antibodies in SLE patients and asymptomatic relatives. Clin Exp Immunol 25 (1976) 377-382
124. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349 (2003) 1526-1533
125. Sinico R.A., Radice A., Ikehata M., et al. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann NY Acad Sci 1050 (2005) 193-200
126. Siegert C.E., and Daha M.R. C1q as antigen in humoral autoimmune responses. Immunobiology 199 (1998) 295-302
127. Kaburaki J., Kuwana M., Yamamoto M., Kawai S., and Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 54 (1997) 209-213
128. Bell S.A., Du Clos T.W., Khursigara G., Picazo J.J., and Rubin R.L. Autoantibodies to cryptic epitopes of C-reactive protein and other acute phase proteins in the toxic oil syndrome. J Autoimmun 8 (1995) 293-303
129. Bell S.A., Faust H., Schmid A., and Meurer M. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 113 (1998) 327-332
130. Sjöwall C., Eriksson P., Almer S., and Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren's syndrome, rheumatoid arthritis, or inflammatory bowel disease. J Autoimmun 19 (2002) 155-160
131. Sjöwall C., Bengtsson A.A., Sturfelt G., and Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 6 (2004) R87-R94
132. Robey F.A., Jones K.D., and Steinberg A.D. C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med 161 (1985) 1344-1356
133. Rosenau B.J., and Schur P.H. Antibodies to C-reactive protein. Ann Rheum Dis 65 (2006) 674-676
134. Figueredo M.A., Rodriguez A., Ruiz-Yagüe M., et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 33 (2006) 1980-1986
135. Mathsson L., Åhlin E., Sjöwall C., Skogh T., Rönnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies. Clin Exp Immunol in press, (doi:10.1111/j.1365-2249.2006.03313.x).
136. Roos A., Bouwman L.H., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Stahl G.L., and Daha M.R. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 167 (2001) 2861-2868
137. Sato R., Matsushita M., Miyata M., Sato Y., Kasukawa R., and Fujita T. Substances reactive with mannose-binding protein (MBP) in sera of patients with rheumatoid arthritis. Fukushima J Med Sci 43 (1997) 99-111
138. Seelen M.A., Trouw L.A., van der Hoorn J.W., et al. Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol 134 (2003) 335-343
139. Takahashi R., Tsutsumi A., Ohtani K., et al. Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus. Clin Exp Immunol 136 (2004) 585-590
140. Mok M.Y., Jack D.L., Lau C.S., et al. Antibodies to mannose binding lectin in patients with systemic lupus erythematosus. Lupus 13 (2004) 522-528
141. Gupta B., Raghav S.K., Agrawal C., Chaturvedi V.P., Das R.H., and Das H.R. Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance. J Autoimmun 27 (2006) 125-133
142. Rosenau B.J., and Schur P.H. Antibody to serum amyloid A. J Autoimmun 23 (2004) 179-182
143. Zandman-Goddard G., Blank M., Langevitz P., et al. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis 64 (2005) 1698-1702
144. Navratil J.S., and Ahearn J.M. Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus. Curr Rheumatol Rep 3 (2001) 191-198
145. Jönsen A., Bengtsson A.A., Sturfelt G., and Truedsson L. Analysis of HLA DR, HLA DQ, C4A, FcγRIIa, FcγRIIIa, MBL, and IL-1ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcγRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Res Ther 6 (2004) R557-R562
146. Takahashi R., Tsutsumi A., Ohtani K., et al. Association of mannose binding lectin (MBL) gene polymorphism and serum MBL concentration with characteristics and progression of systemic lupus erythematosus. Ann Rheum Dis 64 (2005) 311-314
147. Saevarsdottir S., Vikingsdottir T., and Valdimarsson H. The potential role of mannan-binding lectin in the clearance of self-components including immune complexes. Scand J Immunol 60 (2004) 23-29
148. Uwatoko S., Aotsuka S., Okawa M., et al. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol 30 (1984) 104-116
149. Wener M.H., Uwatoko S., and Mannik M. Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum 32 (1989) 544-551
150. Bondanza A., Zimmermann V.S., Dell'Antonio G., et al. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum 50 (2004) 1549-1560
151. Tai A.W., and Newkirk M.M. An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Clin Exp Immunol 120 (2000) 188-193
152. Vossenaar E.R., and van Venrooij W.J. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 6 (2004) 107-111
153. Samberg N.L., Bray R.A., Gewurz H., Landay A.L., and Potempa L.A. Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes. Cell Immunol 116 (1988) 86-98
154. Bray R.A., Samberg N.L., Gewurz H., Potempa L.A., and Landay A.L. C-reactive protein antigenicity on the surface of human peripheral blood lymphocytes. Characterization of lymphocytes reactive with anti-neo-CRP. J Immunol 140 (1988) 4271-4278
155. Mold C., Baca R., and Du Clos T.W. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through FcγRs. J Autoimmun 19 (2002) 147-154
156. Jiang H.X., Siegel J.N., and Gewurz H. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J Immunol 146 (1991) 2324-2330
157. Das T., Sen A.K., Kempf T., Pramanik S.R., Mandal C., and Mandal C. Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J 373 (2003) 345-355
158. Das T., Mandal C., and Mandal C. Variations in binding characteristics of glycosylated human C-reactive proteins in different pathological conditions. Glycoconj J 20 (2004) 537-543
159. Seelen M.A., van der Bijl E.A., Trouw L.A., et al. A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. Rheumatology 44 (2005) 111-119
160. Nakahara C., Kanemoto K., Saito N., et al. C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol 55 (2001) 365-370
161. Zuniga R., Markowitz G.S., Arkachaisri T., Imperatore E.A., D'Agati V.D., and Salmon J.E. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and Fcγ receptor type IIA alleles. Arthritis Rheum 48 (2003) 460-470
162. Kravitz M.S., and Shoenfeld Y. Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases?. Nat Clin Pract Rheumatol 2 (2006) 481-490
163. Trouw L.A., Groeneveld T.W., Seelen M.A., et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114 (2004) 679-688